phospho-CDKN1B (Ser10)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 20074R
英文名称phospho-CDKN1B (Ser10)
中文名称磷酸化笔27抗体/周期素依赖激酶抑制剂
别 名p27 KIP 1 (phospho S10); p-p27 KIP 1 (phospho S10); p27Kip1(Phospho-Ser10); p-p27Kip1(Ser10); p-p27Kip1(S10); CDN1B_HUMAN; AA408329; AI843786; Cdki1b; CDKN 1B; CDKN 4; CDKN1B; CDKN1B; CDKN4; CDKN4; Cyclin Dependent Kinase Inhibitor 1B; Cyclin Dependent Kinase Inhibitor 1B; Cyclin dependent kinase inhibitor p27; Cyclin dependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor 1B (p27, Kip1); Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor p27 Kip1; KIP 1; KIP1; MEN1B; MEN4; OTTHUMP00000195098; OTTHUMP00000195099; p27; p27 Kip1; P27-like cyclin-dependent kinase inhibitor; P27KIP1.
说 明 书100ul 200ul
研究领域**学 细胞周期蛋白 激酶和磷酸酶
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-CDKN1B (Ser10)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, Sheep, Guinea Pig,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg/Test ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量22kDa
细胞定位细胞核 细胞浆
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthetic peptide derived from human phospho-CDKN1B (Ser10):NG(p-S)PS
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-CDKN1B (Ser10)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. [provided by RefSeq, Jul 2008]
Function:
Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry.
Subunit:
Forms a ternary compex with CCNE1/CDK2/CDKN1B.
Subcellular Location:
Nucleus. Cytoplasm. Endosome. Note=Nuclear and cytoplasmic in quiescent cells. AKT-or RSK-mediated phosphorylation on Thr-198, binds 14-3-3, translocates to the cytoplasm and promotes cell cycle progression. Mitogen-activated UHMK1 phosphorylation on Ser-10 also results in translocation to the cytoplasm and cell cycle progression. Phosphorylation on Ser-10 facilitates nuclear export. Translocates to the nucleus on phosphorylation of Tyr-88 and Tyr-89. Colocalizes at the endosome with SNX6; this leads to lysosomal degradation.
Tissue Specificity:
Expressed in all tissues tested. Highest levels in skeletal muscle, lowest in liver and kidney.
Post-translational modifications:
Phosphorylated; phosphorylation occurs on serine, threonine and tyrosine residues. Phosphorylation on Ser-10 is the major site of phosphorylation in resting cells, takes place at the G(0)-G(1) phase and leads to protein stability. Phosphorylation on other sites is greatly enhanced by mitogens, growth factors, cMYC and in certain cancer cell lines. The phosphorylated form found in the cytoplasm is inactivate. Phosphorylation on Thr-198 is required for interaction with 14-3-3 proteins. Phosphorylation on Thr-187, by CDK2 leads to protein ubiquitination and proteasomal degradation. Tyrosine phosphorylation promotes this process. Phosphorylation by PKB/AKT1 can be suppressed by LY294002, an inhibitor of the catalytic subunit of PI3K. Phosphorylation on Tyr-88 and Tyr-89 has no effect on binding CDK2, but is required for binding CDK4. Dephosphorylated on tyrosine residues by G-CSF.
Ubiquitinated; in the cytoplasm by the KPC complex (composed of RNF123/KPC1 and UBAC1/KPC2) and, in the nucleus, by SCF(SKP2). The latter requires prior phosphorylation on Thr-187. Ubiquitinated; by a TRIM21-containing SCF(SKP2)-like complex; leads to its degradation.
DISEASE:
Defects in CDKN1B are the cause of multiple endocrine neoplasia type 4 (MEN4) [MIM:610755]. Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2.
Similarity:
Belongs to the CDI family.
SWISS:
P46527
Gene ID:
1027
phospho-CDKN1B (Ser10)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-CDKN1B (Ser10)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 MSI2 MSI2蛋白抗体
合格 MSL1v1/CENP36 着丝粒蛋白36抗体
合格 MSL3L2 MSL3L2蛋白抗体
合格 MSTO1 MSTO1蛋白抗体
合格 MTERFD2 线粒体转录终止因子2抗体
合格 MTFMT MTFMT蛋白抗体
合格 MTHFD2L 亚甲基四氢叶酸脱氢酶2样蛋白抗体
合格 MTHFSD MTHFSD蛋白抗体
合格 MTMR12 肌微管素相关蛋白12抗体
合格 MTMR7 肌微管素相关蛋白7抗体
合格 MTMR9 肌微管素相关蛋白9抗体
合格 合格 CCR9 细胞表面趋化因子受体9抗体
合格 MTO1 MTO1蛋白抗体
合格 MTRF1 线粒体释放因子1样蛋白抗体
合格 合格 mtRNA polymerase 线粒体RNA聚合酶抗体
合格 合格 MTX1 MTX1蛋白抗体
合格 MTX2 MTX2蛋白抗体
合格 MTX3 MTX3蛋白抗体
合格 IL12 白介素12抗体
合格 合格 CRMP2/TOAD64 二氢嘧啶酶相关蛋白2抗体
合格 OR52R1 嗅觉受体52R1抗体
合格 OR5B12 嗅觉受体5AU12抗体
合格 OR5D14 嗅觉受体5D14抗体
合格 OR5H6 嗅觉受体5H6抗体
合格 合格 GLUR2 谷氨酸受体2抗体
合格 Orai1 嗅觉受体ai1抗体
合格 ORC4L ORC4L蛋白抗体
合格 合格 Orexin Receptor 1 丘脑分泌素受体1抗体
合格 GRM1 促代谢型谷氨酸受体1抗体
合格 HLADQA1 + HLADQA2 组织相容性抗原DQA1/DQA2抗体
合格 HMBOX1 HMBOX1蛋白抗体
合格 CD11a 整合素αL抗体
合格 HMG2L1 高迁移率族蛋白2样蛋白1抗体
合格 HMGN3 高迁移率族蛋白N3抗体